FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha® (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. SPY
2. USO
3. IONQ
4. IONS
5. ACN
6. AZN
7. ROIV
8. AAPL
9. HOOD
10. QCOM

Go back to FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha® (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events
Amgen Inc (NASDAQ: AMGN) Delayed: 393.17 -44.06 (10.08%)
Previous Close $437.23    52 Week High $176.85 
Open $408.90    52 Week Low $133.64 
Day High $410.03    P/E 59.21 
Day Low $391.17    EPS $6.64 
Volume 6,548,206